Michael Byrnes

Michael Byrnes (finance chief) discloses dealings in 2 companies, chiefly Ocera Therapeutics, Inc. and eFFECTOR Therapeutics, Inc. Over a trading history stretching from 1 October 2014 to 15 May 2024, the count stands at 13 filings.

The open-market record is one-sided, with 5 purchases worth €57k and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 6 share grants.

In size, the median ticket on the buying side is €7,620. Of 3 purchases, 1 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

On 17 May 2024 came the latest disclosure, a share grant in eFFECTOR Therapeutics, Inc. The most recent open-market purchase was published on 7 June 2022, 1,600 days ago. Typically, a trade is published a median of 1 day after it takes place. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.